A/Prof. Simunovic is actively engaged in research into emerging treatments for retinal disease, visual function and experimental vitreoretinal surgery. If you are seeing A/Prof Simunovic as a patient and are interested in participating in a research project, please discuss this with him at your appointment. If you are a prospective research trainee (pre- or -post-doctoral) interested in working on one of these projects, please see his University of Sydney webpage (http://sydney.edu.au/medicine/people/academics/profiles/matthew.simunovic.php).
This is a pre-clinical trial aimed at vision restoration in a model of inherited retinal degeneration and is supported by the Sydney Medical School Foundation.
Hereditary diseases of the retina affect up to 1 in 3,000 individuals and are now the commonest cause of blindness registration in persons of working age. This project is aimed at:
This is a phase III clinical trial of a ciliary neurotrophic factor implant for patients with macular telangiectasia II (MacTel II; ClinicalTrials.gov identifier NCT03316300). The Sydney arm is being conducted by the Macula Research Group at the Save Sight Institute (http://www.savesightinstitute.org.au/research-units/macula-research-group/current-upcoming-clinical-trials/).
Seitz IP, Jolly JK, Fischer MD, Simunovic MP. Colour discrimination ellipses in choroideremia. Graefes Arch Clin Exp Ophthalmol. 2018 Apr;256(4):665-673. doi: 10.1007/s00417-018-3921-0. Epub 2018 Feb 5.
Edwards TL, Cottriall CL, Xue, K, Simunovic MP, Ramsden JD, Zrenner E, MacLaren RE. Assessment of the electronic retinal implant in restoring vision to blind patients with end-stage retinitis pigmentosa. Ophthalmology. 2018 Mar;125(3):432-443. doi: 10.1016/j.ophtha.2017.09.019. Epub 2017 Oct 27.
Edwards TL, Williams J, Patrício MI, Simunovic MP, Shanks M, Clouston P, MacLaren RE. Novel non-contiguous exon duplication in choroideremia. Clin Genet. 2018 Jan;93(1):144-148. doi: 10.1111/cge.13021. Epub 2017 Apr 19.
Simunovic, MP, Jolly, JK, Xue, K, MacLaren, RE. Structural and functional recovery following limited iatrogenic macular detachment for retinal gene therapy. JAMA Ophthalmol. 2017 Mar 1;135(3):234-241.
Simunovic, MP, Jolly, JK, Xue, K, Edwards, TL, Groppe, M, Downes, SM, MacLaren, RE. The spectrum of CHM gene mutations in choroideremia and their relationship to clinical phenotype. Invest Ophthalmol Vis Sci. 2016; 57: 6033-6039.
Edwards TL, Jolly JK, Groppe M, Barnard AR, Cottriall CL, Tolmachova T, Black, GC, Webster, AR, Lotery, AJ, Holder, GE, Xue, K, Downes, SM, Simunovic, MP, Seabra, MC, & MacLaren, RE. Visual acuity after retinal gene therapy for choroideremia. N Engl J Med. 2016;374(20):1996-8.
Rush RB, Simunovic MP, Vandiver L, Aragon AV, 2nd, Ysasaga JE. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics. Retina. 2014;34(5):846-52.
Rush RB, Simunovic MP, Aragon AV, 2nd, Ysasaga JE. Postoperative macular hole formation after vitrectomy with internal limiting membrane peeling for the treatment of epiretinal membrane. Retina. 2014;34(5):890-6.
Rush R, Simunovic MP, Sheth S, Chang A, Hunyor AP. 23-Gauge Pars Plana Vitrectomy Versus Scleral Buckling Versus Combined Pars Plana Vitrectomy-Scleral Buckling for Medium-Complexity Retinal Detachment Repair. Asia Pac J Ophthalmol (Phila). 2014;3(4):215-9.
Rush RB, Simunovic MP, Sheth S, Kratz A, Hunyor AP. Pars plana vitrectomy versus combined pars plana vitrectomy-scleral buckle for secondary repair of retinal detachment. Ophthalmic Surg Lasers Imaging Retina. 2013;44(4):374-9.
Rush RB, Simunovic MP, Hunyor AP. Twenty-Three-Gauge Pars Plana Vitrectomy With Inferior Retinectomy and Postoperative Perfluoro-n-Octane Retention for Retinal Detachment Repair. Asia Pac J Ophthalmol (Phila). 2013;2(4):232-6.
Simunovic MP, Rush RB, Hunyor AP, Chang AA. Endophthalmitis following intravitreal injection versus endophthalmitis following cataract surgery: clinical features, causative organisms and post-treatment outcomes. Br J Ophthalmol. 2012;96(6):862-6.
Michaelides M, Johnson S, Simunovic MP, Bradshaw K, Holder G, Mollon JD, et al. Blue cone monochromatism: a phenotype and genotype assessment with evidence of progressive loss of cone function in older individuals. Eye (Lond). 2005;19(1):2-10.
Michaelides M, Aligianis IA, Holder GE, Simunovic M, Mollon JD, Maher ER, et al. Cone dystrophy phenotype associated with a frameshift mutation (M280fsX291) in the alpha-subunit of cone specific transducin (GNAT2). Br J Ophthalmol. 2003;87(11):1317-20.
Gregory-Evans K, Kelsell RE, Gregory-Evans CY, Downes SM, Fitzke FW, Holder GE, Simunovic M, et al. Autosomal dominant cone-rod retinal dystrophy (CORD6) from heterozygous mutation of GUCY2D, which encodes retinal guanylate cyclase. Ophthalmology. 2000;107(1):55-61.
Simunovic MP. The cone dystrophies. Cambridge: University of Cambridge; 1999.